UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 226,048 Shares of Royalty Pharma PLC $RPRX

Key Points

• UBS Asset Management increased its stake in Royalty Pharma PLC by 8.6%, owning approximately 2.85 million shares valued at about $88.7 million as of its latest SEC filing.
• Royalty Pharma declared a quarterly dividend of $0.22 per share, with an annualized yield of 2.4% and a payout ratio of about 50.87%.
• Despite recent institutional buying trends, Royalty Pharma's stock has a market cap of $21.2 billion and is currently trading at $36.36, down 0.9%.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 8.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,847,934 shares of the biopharmaceutical company's stock after purchasing an additional 226,048 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.49% of Royalty Pharma worth $88,656,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Two Sigma Advisers LP increased its stake in Royalty Pharma by 21.1% in the 4th quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company's stock worth $93,703,000 after purchasing an additional 640,000 shares during the period. Victory Capital Management Inc. increased its stake in Royalty Pharma by 270.4% in the 1st quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company's stock worth $112,788,000 after purchasing an additional 2,644,923 shares during the period. AQR Capital Management LLC increased its stake in Royalty Pharma by 37.0% in the 1st quarter. AQR Capital Management LLC now owns 2,608,090 shares of the biopharmaceutical company's stock worth $80,381,000 after purchasing an additional 704,414 shares during the period. Invesco Ltd. increased its stake in Royalty Pharma by 34.1% in the 1st quarter. Invesco Ltd. now owns 1,284,418 shares of the biopharmaceutical company's stock worth $39,984,000 after purchasing an additional 326,525 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Royalty Pharma by 7.5% in the 1st quarter. Alliancebernstein L.P. now owns 1,241,051 shares of the biopharmaceutical company's stock worth $38,634,000 after purchasing an additional 86,873 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Up 0.3%

Royalty Pharma stock traded up $0.09 on Thursday, hitting $35.73. 9,157,677 shares of the stock traded hands, compared to its average volume of 4,237,795. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 0.74. The firm has a market cap of $20.84 billion, a P/E ratio of 20.65, a price-to-earnings-growth ratio of 2.23 and a beta of 0.58. The business's fifty day simple moving average is $36.34 and its 200 day simple moving average is $34.34. Royalty Pharma PLC has a 1 year low of $24.05 and a 1 year high of $38.00.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.10 by $0.04. The business had revenue of $578.67 million during the quarter, compared to analyst estimates of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. As a group, sell-side analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Friday, August 15th. Royalty Pharma's payout ratio is 50.87%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on RPRX shares. Wall Street Zen cut Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. Morgan Stanley boosted their target price on Royalty Pharma from $51.00 to $54.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Finally, Citigroup boosted their target price on Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat, Royalty Pharma currently has an average rating of "Buy" and a consensus price target of $48.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.